Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology Development.
CD137 (4-1BB, TNFRSF9) is a critical costimulatory receptor in the TNF receptor superfamily, expressed on activated T cells, natural killer (NK) cells, and dendritic cells. As a potent amplifier of adaptive immunity, CD137 has emerged as a high-priority target for immuno-oncology, though clinical development has navigated challenges between efficacy and hepatotoxicity. The current pipeline has shifted toward bispecific formats and conditional agonists to spatially restrict immune activation within the tumor microenvironment, with first-generation agents (Urelumab, Utomilumab) defining the efficacy/toxicity trade-off.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TNFRSF9 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TNFRSF9 ECD-Fc Fusion Protein / Mutant Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View TNFRSF9 Products |
| Gene Delivery | TNFRSF9 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for reporter and flow cytometry assays. |
View TNFRSF9 Products |
| Benchmark Ab | Anti-TNFRSF9 (Urelumab / Utomilumab Sequence) Recombinant positive control for agonist benchmarking and epitope binning. |
View TNFRSF9 Products |
| Validator | TNFRSF9 siRNA Set For knockdown verification and assay specificity controls. |
View TNFRSF9 Products |
| Related Target A | TNFSF9 (4-1BBL) Natural ligand for competitive binding, SPR, and blocking assay design. |
View TNFSF9 Products |
| Related Target B | CD274 (PD-L1) Synergistic checkpoint combination partner; critical for bispecific R&D and tumor-conditional activation. |
View CD274 Products |
| Related Target C | TNFRSF4 (OX40) TNF receptor superfamily homolog for subfamily cross-reactivity and selectivity screening. |
View TNFRSF4 Products |
| Related Target D | CD3E T cell engager bispecific component for T-cell redirection. |
View CD3E Products |
| Related Target E | ERBB2 (HER2) Tumor-associated antigen for localized 4-1BB activation in solid tumors. |
View ERBB2 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species (Cyno/Mouse) ortholog evaluation for IND-enabling tox | Human/Mouse/Cyno TNFRSF9 ortholog ECD-Fc proteins available with >95% purity, Endotoxin controlled, Sequence Verified. |
| Epitope-dependent agonist potency screening & liver toxicity epitope mapping | Clinical benchmark antibodies (Urelumab and Utomilumab biosimilar sequences) for epitope binning; full-length TNFRSF9 Lentivirus for native conformation cell-based assays. |
| TNFRSF subfamily off-target specificity (OX40, GITR, CD40) | Homolog panel proteins strictly verified by mass spec for counter-screening and selectivity exclusion. |
| Cell-based bridging assays for bispecifics (TAAx4-1BB, PD-L1x4-1BB) | Lentivirus-mediated stable cell line construction for robust co-culture systems and dual-antigen binding validation. |
| False positive elimination in binding assays | Validated siRNA included for specificity checks and target engagement confirmation. |
Live TNFRSF9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TNFRSF9 (CD137) therapeutics is intensifying, with major players shifting focus from traditional agonist mAbs to tumor-conditional formats including bispecifics (e.g., PD-L1×4-1BB, TAA×4-1BB), Fc-engineered constructs, and probody platforms. As first-generation agents (Urelumab, Utomilumab) defined the efficacy/toxicity trade-off, the next wave of R&D targets liver-safe epitopes, conditional activation within the tumor microenvironment, and integration with checkpoint blockade. CAR-T co-stimulation using 4-1BB domains also remains a key area.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonist mAb | Bristol Myers Squibb (Urelumab), Pfizer (Utomilumab) | Solid Tumors, Melanoma | FcγR Crosslinking & Reporter Assays (need high-purity ECD-Fc and benchmark antibodies) |
| Bispecific (CD137xPD-1) | Genentech, AstraZeneca, Inmagene | Solid Tumors | Cross-linking Validation (need cross-reactive Abs and CD137 Lentivirus reporter cells) |
| Bispecific (TAAx4-1BB) | Genmab, BioNTech, Numab, Lepu Biotech | HER2+ Cancers, EGFR+ Cancers | Conditional Activation Assay (need tumor antigen + CD137 co-culture systems) |
| Conditional/Probody | Crescendo Biologics, BioAtla | Solid Tumors | pH-dependent Binding Assay (need mutant ECD variants for specific conformational states) |
| CAR-T Co-stimulation | Bristol Myers Squibb, Novartis | Hematologic Malignancies | Costimulatory Domain Validation (need full-length 4-1BB expressing target cells via Lentivirus) |
Note: Product links (e.g., View TNFRSF9 Products) are placeholders for TarMart catalog entries and should be replaced with live URLs.